Copyright
©The Author(s) 2022.
World J Cardiol. Jun 26, 2022; 14(6): 329-342
Published online Jun 26, 2022. doi: 10.4330/wjc.v14.i6.329
Published online Jun 26, 2022. doi: 10.4330/wjc.v14.i6.329
Trial eponym, drugs | Background GLP-1RA + SGLT-2I therapy; n | Active arm (n/N), % or rate-per 100-patient-yr1 | Placebo arm (n/N), % or rate-per 100-patient-yr1 | HR, (95%CI) | P value of interaction |
3-point composite of major adverse cardiovascular events outcome | |||||
CANVAS[46], Canagliflozin | Yes; 407 | NR | NR | 0.73 (0.36-1.46) | 0.94 |
No; 9735 | NR | NR | 0.86 (0.76-0.98) | ||
DECLARE-TIMI[47], Dapagliflozin | Yes; 750 | 31/397, 7.8% | 31/353, 8.8% | 0.87 (0.53-1.43) | 0.84 |
No; 16410 | 725/8185, 8.9% | 772/8225, 9.4% | 0.94 (0.85-1.04) | ||
VERTIS-CV[48], Ertugliflozin | Yes; 277 | 21/192, 3.541 | 9/85, 3.791 | 0.94 (0.43-2.05) | NR |
No; 7961 | 632/5301, 3.911 | 318/2660, 4.021 | 0.97 (0.85-1.11) | ||
EXSCEL[43], Exenatide QW | Yes; 11442 | NR/572, 3.291 | NR/572, 4.811 | 0.68 (0.39-1.17) | NR |
No | NR | NR | NR | ||
AMPLITUDE-O[45], Efpeglenatide | Yes; 618 | 25/412, 6.1%, 3.41 | 17/206, 8.3%, 5.01 | 0.70 (0.37-1.30) | 0.68 |
No; 3458 | 164/2305, 7.1%, 4.01 | 108/1153, 9.4%, 5.41 | 0.74 (0.58-0.94) | ||
Heart failure hospitalization outcome | |||||
DECLARE-TIMI[47], Dapagliflozin | Yes; 750 | 4/397, 1.0% | 18/353, 5.1% | 0.20 (0.07-0.60) | 0.01 |
No; 16410 | 208/8185, 2.5% | 268/8225, 3.3% | 0.77 (0.64-0.92) | ||
AMPLITUDE-O[45], Efpeglenatide | Yes; 618 | 3/412, 0.7%; 0.41 | 6/206, 2.9%, 1.61 | 0.23 (0.05-0.97) | 0.35 |
No; 3458 | 37/2305, 1.6%, 0.91 | 25/1153, 2.2%, 1.21 | 0.70 (0.42-1.17) | ||
Renal outcome | |||||
DECLARE-TIMI[47], Dapagliflozin3 | Yes; 750 | 4/397, 1.0% | 10/353, 2.8% | 0.36 (0.11-1.15) | 0.49 |
No; 16410 | 123/8185, 1.5% | 228/8225, 2.8% | 0.54 (0.43-0.67) | ||
AMPLITUDE-O[45], Efpeglenatide4 | Yes; 618 | 37/412, 9.0%, 5.11 | 34/206, 16.5%, 10.01 | 0.52 (0.33-0.83) | 0.38 |
No; 3458 | 316/2305, 13.7%, 8.21 | 216/1153, 18.7%, 11.91 | 0.70 (0.59-0.83) |
- Citation: Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342
- URL: https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i6.329